EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL ‐8 from CD248 ‐expressing cancer‐associated fibroblasts generates cisplatin resistance in non‐small cell lung cancer

Jieheng Wu iD, Qiaoling Zhang, Jiangwei Wu, Zeyang Yang, Xinlei Liu, Chunju Lou, Xuanyin Wang, Jiangying Peng, Jinyuan Zhang, Zhenling Shang, Jing Xiao, Nianxue Wang und 7 weitere

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Jieheng Wu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Guizhou Medical University, Guiyang, Guizhou, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cancer-Associated Fibroblasts, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China Cultivation Program of Guizhou Medical University, Flexible Talent Introduction Project of Guizhou Medical University, Basic Research Program of Guizhou Provincial Department of Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy‐resistant non‐small cell lung cancer (NSCLC) presents a substantial barrier to effective care. It is still unclear how cancer‐associated fibroblasts (CAFs) contribute to NSCLC resistance to chemotherapy. Here, we found that CD248 + CAFs released IL‐8 in NSCLC, which, in turn, enhanced the cisplatin (CDDP) IC50 in A549 and NCI‐H460 while decreasing the apoptotic percentage of A549 and NCI‐H460 in vitro. The CD248 + CAFs‐based IL‐8 secretion induced NSCLC chemoresistance by stimulating nuclear factor kappa B (NF‐κB) and elevating ATP‐binding cassette transporter B1 (ABCB1). We also revealed that the CD248 + CAFs‐based IL‐8 release enhanced cisplatin chemoresistance in NSCLC mouse models in vivo. Relative to wild‐type control mice, the CD248 conditional knockout mice exhibited significant reduction of IL‐8 secretion, which, in turn, enhanced the therapeutic efficacy of cisplatin in vivo. In summary, our study identified CD248 activates the NF‐κB axis, which, consecutively induces the CAFs‐based secretion of IL‐8, which promotes NSCLC chemoresistance. This report highlights a potential new approach to enhancing the chemotherapeutic potential of NSCLC‐treating cisplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCancer-Associated FibroblastsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmInterleukin-8Lung NeoplasmsAnimalsMiceAntigens, CDAntigens, NeoplasmCell Line, TumorCell ProliferationCisplatinNF-kappa BHumans

Stichwörter der Autor:innen

CD248IL-8cancer-associated fibroblastschemoresistancenon-small cell lung cancer

Substanzen

Antigens, CDAntigens, NeoplasmAntineoplastic AgentsCD248 protein, mouseCisplatinInterleukin-8NF-kappa BCD248 protein, human

Autor:innen und Institutionen

  • Department of Immunology, Guizhou Medical University, Guiyang, Guizhou, China.
  • The State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi'an, China.
  • Key Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province, Engineering Research Center of Cellular Immunotherapy of Guizhou Province, School of Biology and Engineering, Guizhou Medical University,…
  • Key Laboratory of Biology and Medical Engineering, Immune Cells and Antibody Engineering Research Center of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou, China.
  • Guizhou Prenatal Diagnsis Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
  • Department of Pharmaceutical analysis, Zunyi Medical University, Zunyi, Guizhou, China.

ORCID-Profile: Jieheng Wu

Förderung

  • National Natural Science Foundation of China Cultivation Program of Guizhou Medical University
  • Flexible Talent Introduction Project of Guizhou Medical University
  • Basic Research Program of Guizhou Provincial Department of Science and Technology Agency
  • High-level Talent Startup Fund Project of Guizhou Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Wu, J., Zhang, Q., Wu, J., Yang, Z., Liu, X., Lou, C., Wang, X., Peng, J., Zhang, J., Shang, Z., Xiao, J., Wang, N., Zhang, R., Zhou, J., Wang, Y., Hu, Z., Zhang, R., Zhang, J., & Zeng, Z. (2024). IL ‐8 from CD248 ‐expressing cancer‐associated fibroblasts generates cisplatin resistance in non‐small cell lung cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18185

Vancouver

Wu J, Zhang Q, Wu J, Yang Z, Liu X, Lou C, et al. IL ‐8 from CD248 ‐expressing cancer‐associated fibroblasts generates cisplatin resistance in non‐small cell lung cancer. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18185

BibTeX
@article{Wu2024,
  author = {Wu, Jieheng and Zhang, Qiaoling and Wu, Jiangwei and Yang, Zeyang and Liu, Xinlei and Lou, Chunju and Wang, Xuanyin and Peng, Jiangying and Zhang, Jinyuan and Shang, Zhenling and Xiao, Jing and Wang, Nianxue and Zhang, Ruya and Zhou, Jinyao and Wang, Yun and Hu, Zuquan and Zhang, Rui and Zhang, Jian and Zeng, Zhu},
  title = {IL ‐8 from CD248 ‐expressing cancer‐associated fibroblasts generates cisplatin resistance in non‐small cell lung cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18185}
}
Kostenlos starten →